Green light for ARI0002h CAR-T developed by Clínic-IDIBAPS for patients with multiple myeloma
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
The ”la Caixa” Foundation will allocate 4.6 million euros to promoting research at the Hospital Clínic Barcelona, in order to develop new, personaliz1
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
IDIBAPS looks for talented professionals to meet the needs that appear periodically.
Enter